Tsubota Laboratory Incorporated (JP:4890)
:4890
Want to see JP:4890 full AI Analyst Report?
Top Page
Tsubota Laboratory Incorporated
(4890)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥263.00
▼(-22.65% Downside)
Action:Reiterated
Date:05/16/26
The score is primarily weighed down by sharp 2026 fundamental deterioration (major revenue drop, deep losses) and persistent negative cash flow, with additional pressure from a bearish technical setup (below key moving averages, negative MACD). A low-debt balance sheet provides some resilience but is not enough to offset the current operating and cash-burn risks.
Positive Factors
Conservative balance sheet
Sustained low leverage provides structural resilience versus operational volatility. A conservatively financed balance sheet reduces refinancing risk, preserves borrowing capacity for R&D or working capital, and lengthens runway while management works to restore operating performance.
Negative Factors
Severe revenue collapse
An 85% revenue drop is a structural alarm, eroding scale needed to cover fixed costs and fund R&D. Such a collapse can unwind key commercial relationships, delay pipelines, and force expense cuts that impair long-term growth prospects unless revenue recovery is achieved within several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Sustained low leverage provides structural resilience versus operational volatility. A conservatively financed balance sheet reduces refinancing risk, preserves borrowing capacity for R&D or working capital, and lengthens runway while management works to restore operating performance.
Read all positive factors
Tsubota Laboratory Incorporated (4890) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.04B
Dividend YieldN/A
Average Volume (3M)31.02K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue Growth-85.26%
EPS Growth-468.26%
CountryJP
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)6.97
Shares Outstanding25,794,300
10 Day Avg. Volume26,720
30 Day Avg. Volume31,016
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.77
Price to Sales (P/S)37.86
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tsubota Laboratory Incorporated Business Overview & Revenue Model
Company Description
Tsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan....
How the Company Makes Money
null...
Tsubota Laboratory Incorporated Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
73
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36B | 200.02M | 1.36B | 673.53M | 954.69M | 640.92M |
| Gross Profit | 1.15B | 131.57M | 1.15B | -9.48M | 686.83M | 528.76M |
| EBITDA | 219.47M | -765.24M | 262.46M | -609.24M | 206.22M | 173.87M |
| Net Income | 178.16M | -761.82M | 205.77M | -641.32M | 90.18M | 153.32M |
Balance Sheet | ||||||
| Total Assets | 2.02B | 1.32B | 2.50B | 2.30B | 2.67B | 1.62B |
| Cash, Cash Equivalents and Short-Term Investments | 1.47B | 969.85M | 1.54B | 1.88B | 2.16B | 1.17B |
| Total Debt | 85.26M | 69.21M | 90.38M | 116.90M | 139.34M | 223.82M |
| Total Liabilities | 627.88M | 454.92M | 915.85M | 927.93M | 722.59M | 873.44M |
| Stockholders Equity | 1.39B | 863.86M | 1.59B | 1.37B | 1.95B | 744.35M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -586.61M | -331.75M | -313.35M | -15.27M | 582.69M |
| Operating Cash Flow | 0.00 | -577.83M | -317.75M | -301.35M | 28.49M | 654.91M |
| Investing Cash Flow | 0.00 | -8.41M | -14.55M | -12.00M | -54.03M | -72.23M |
| Financing Cash Flow | 0.00 | 17.23M | -12.25M | 35.74M | 1.01B | -18.53M |
Tsubota Laboratory Incorporated Technical Analysis
Positive
340.00
Price Trends
311.10
Positive
327.85
Negative
343.76
Negative
Market Momentum
-2.21
Negative
49.98
Neutral
75.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Positive. The current price of 340 is above the 20-day moving average (MA) of 318.65, above the 50-day MA of 311.10, and below the 200-day MA of 343.76, indicating a neutral trend. The MACD of -2.21 indicates Negative momentum. The RSI at 49.98 is Neutral, neither overbought nor oversold. The STOCH value of 75.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4890.
Tsubota Laboratory Incorporated Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥439.63B | 14.57 | 11.37% | 3.04% | 5.08% | 2.07% | |
67 Neutral | ¥368.12B | 16.82 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥580.69B | 17.44 | 15.71% | 0.96% | 15.07% | 72.98% | |
62 Neutral | ¥947.68B | 19.41 | ― | 1.72% | ― | ― | |
60 Neutral | ¥499.01B | 16.97 | ― | 0.93% | 6.74% | 6.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ¥7.04B | -9.94 | ― | ― | -85.26% | -468.26% |
* Healthcare Sector Average
JP:4890
Tsubota Laboratory Incorporated
273.00
-104.00
-27.59%
JP:9989
Sundrug Co
3,760.00
-641.52
-14.57%
JP:7649
Sugi Holdings Co
3,081.00
-12.40
-0.40%
JP:3391
TSURUHA Holdings
2,106.50
-90.57
-4.12%
JP:3349
COSMOS Pharmaceutical Corporation
6,269.00
-2,744.15
-30.45%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,850.00
322.32
9.14%
Tsubota Laboratory Incorporated Corporate Events
Tsubota Laboratory Swings to Loss but Projects Sharp Rebound in 2027
May 15, 2026
Tsubota Laboratory reported a sharp downturn in non-consolidated results for the fiscal year ended March 31, 2026, with revenue plunging 85.3% to ¥200 million and swinging from a prior-year profit to a net loss of ¥761 million. The compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.